SOURCE: Tulip BioMed, Inc.

May 01, 2007 08:28 ET

Tulip's Proprietary Disposable Products Exhibited at the American Society for Aesthetic Plastic Surgery's 40th Annual Meeting

SAN DIEGO, CA -- (MARKET WIRE) -- May 1, 2007 -- Tulip BioMed™, Inc. (PINKSHEETS: TPBD), a developer of medical devices and patented technologies for the living tissue markets, including plastic, cosmetic, and orthopedic surgeries, comments on the exhibition of its new disposable instruments for these markets at the national meeting of the American Society for Aesthetic Plastic Surgery (ASAPS) held April 20 - 24, 2007 in New York City.

Tulip BioMed demonstrated its disposable, minimally invasive micro-cannulas for tissue harvest, transfer, re-injection and other surgical uses (already in the market) plus a series of five versatile, disposable cannula models (prototypes) that work with both standard aspiration machines and the syringe method for body sculpting. The response from the meetings attendees indicates the industry's acceptance of disposable devices and the advantages associated with these disposable devices.

ASAPS fosters patient safety through education at its scientific and educational meetings. This ASAPS Meeting 2007 was planned for the experienced surgeon who is familiar with standard aesthetic procedures and wished to learn more about newer, better and safer technologies and techniques to enhance his or her practice. The national meeting showcased a variety of special presentations by respected surgeons with vast knowledge and experience in aesthetic surgery. It also featured useful tips on new devices, including Tulip's products, which can benefit patients worldwide.

By eliminating the reuse of closed-end instruments in soft tissue procedures, Tulip BioMed's disposable instruments help solve cross-contamination issues. The proprietary Smooth Tube Technology is designed to help decrease trauma to the cells that pass through the lumen, increasing the ease at which the instrument passes through the tissue and helps shorten recovery periods for patients.

Doctors and industry professionals who would like to discuss Tulip BioMed's advantages are encouraged to call the company at 800-978-8547.

About Tulip BioMed, Inc.

Tulip BioMed, Inc. (PINKSHEETS: TPBD), a Nevada corporation, has its operations based in San Diego, California. Founded in 2004, Tulip BioMed, Inc. is a medical devices company that manufactures and distributes patented technologies for the living tissue markets, including plastic and cosmetic surgery, biopsy, orthopedic surgery, and stem cell therapy. Tulip BioMed, Inc. is the exclusive licensee of patented syringe connection devices that use the worldwide recognized "Tulip" brand name. Tulip BioMed, Inc. manufactures, markets, and distributes medical devices, adapted with these and other patented technologies, to physicians, clinics, military, health organizations, hospitals and other distribution outlets. For more information go to: Products are available for sale at

Safe Harbor: This press release contains certain forward-looking information about Tulip BioMed, Inc., which is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Words such as "expect(s)," "feel(s)," "believe(s)," "will," "may," "anticipate(s)," and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, financial projections and estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to future operations, products and services; and statements regarding future performance. Such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of Tulip BioMed, Inc., that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include: our lack of operating revenue and earnings history, our need for additional capital to pursue our business strategy. We are a non-reporting company and as such do not make periodic filings with the Securities and Exchange Commission. We trade on the Pink Sheets and there can be no assurances that a liquid market will develop in our securities. Readers are cautioned not to place undue reliance on these forward-looking statements. Tulip BioMed, Inc. does not undertake any obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Contact Information


    Premier Funding Service
    Kelly Black, President
    Email Contact
    Heather Kerwin, Investor Relations
    Email Contact
    (480) 649-8224 Office
    (480) 898-0406 Fax

    For legal and shareholder matters, please contact:
    Attention: Blair Krueger, Esq.
    Managing Partner
    La Jolla Law Building
    5771 La Jolla Boulevard
    La Jolla, California 92037
    Telephone: (858) 729-9997
    Facsimile: (858) 729-9995